{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:04:27Z","timestamp":1782936267442,"version":"3.54.5"},"reference-count":66,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Angiogenesis and immunosuppression promote multiple myeloma (MM) development, and osteolysis is a primary feature of MM. Although immunomodulatory drugs and proteasome inhibitors (PIs) markedly improve the survival of patients with MM, this disease remains incurable. In the bone marrow niche, a chain of ectoenzymes, including CD38, produce immunosuppressive adenosine, inhibiting T cell proliferation as well as immunosuppressive cells. Therefore, anti-CD38 antibodies targeting myeloma cells have the potential to restore T cell responses to myeloma cells. Meanwhile extracellular vesicles (EVs) containing microRNAs, proteins such as cytokines and chemokines, long noncoding RNAs, and PIWI-interacting RNAs have been shown to act as communication tools in myeloma cell\/microenvironment interactions. Via EVs, mesenchymal stem cells allow myeloma cell dissemination and confer PI resistance, whereas myeloma cells promote angiogenesis, myeloid-derived suppressor cell proliferation, and osteoclast differentiation and inhibit osteoblast differentiation. In this review, to understand key processes of MM development involving communication between myeloma cells and other cells in the tumor microenvironment, EV cargo and the non-canonical adenosinergic pathway are introduced, and ectoenzymes and EVs are discussed as potential druggable targets for the treatment of MM patients.<\/jats:p>","DOI":"10.3390\/cancers13122969","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T10:30:25Z","timestamp":1623666625000},"page":"2969","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"given":"Takashi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of Myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance","volume":"134","author":"Kyle","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Martin, T.G., Corzo, K., Chiron, M., Van De Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., and Wiederschain, D. (2019). Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells, 8.","DOI":"10.3390\/cells8121522"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25602","DOI":"10.18632\/oncotarget.4693","article-title":"A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation","volume":"6","author":"Morandi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1458809","DOI":"10.1080\/2162402X.2018.1458809","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+","volume":"7","author":"Morandi","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine Generated in the Bone Marrow Niche through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma","volume":"22","author":"Horenstein","year":"2016","journal-title":"Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2019.00760","article-title":"CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights from Basic Science to Therapy","volume":"10","author":"Horenstein","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1538-7445.NONRNA15-A17","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2017010801","article-title":"Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss","volume":"1","author":"Zahoor","year":"2017","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41388-018-0359-0","article-title":"Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1038\/s41388-019-0788-4","article-title":"piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment","volume":"38","author":"Li","year":"2019","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2014-05-576116","article-title":"Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1","volume":"124","author":"Umezu","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.4712","article-title":"Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression","volume":"239","author":"Wang","year":"2016","journal-title":"J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell\u2013derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-18-2363","article-title":"Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.matbio.2017.09.001","article-title":"Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior","volume":"65","author":"Bandari","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","article-title":"Multiple myelo-ma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis","volume":"12","author":"Raimondo","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6305295","article-title":"Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a","volume":"2017","author":"Cheng","year":"2017","journal-title":"Stem Cells Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41556-018-0040-4","article-title":"Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.019","article-title":"Cellular uptake of extracellular vesicles is mediated by clath-rin-independent endocytosis and macropinocytosis","volume":"266","author":"Verdera","year":"2017","journal-title":"J Controll Release"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1126\/science.1163853","article-title":"The Antisense Transcriptomes of Human Cells","volume":"322","author":"He","year":"2008","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1126\/science.1251456","article-title":"The STAT3-Binding Long Noncoding RNA lnc-DC Controls Human Dendritic Cell Differentiation","volume":"344","author":"Wang","year":"2014","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","article-title":"Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA","volume":"29","author":"Qu","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/bfgp\/elv058","article-title":"Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer","volume":"15","author":"Mohankumar","year":"2016","journal-title":"Briefings Funct. Genom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0606-4","article-title":"MALAT1: A druggable long non-coding RNA for targeted anti-cancer approaches","volume":"11","author":"Amodio","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Butova, R., Vychytilova-Faltejskova, P., Souckova, A., Sevcikova, S., and Hajek, R. (2019). Long Non-Coding RNAs in Multiple Myeloma. Non-Coding RNA, 5.","DOI":"10.3390\/ncrna5010013"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ribatti, D., and Vacca, A. (2018). New Insights in Anti-Angiogenesis in Multiple Myeloma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072031"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: Emerging new players","volume":"7","author":"Desantis","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD+-Metabolizing Ectoenzymes in Remodeling Tumor\u2013Host Interactions: The Human Myeloma Model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: A leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","first-page":"1325","article-title":"Surface antigens of immunocompetent cells. I. Effect of theta and PC.1 alloantisera on the ability of spleen cells to transfer immune responses","volume":"131","author":"Takahasi","year":"1970","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e26246","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ecto-enzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"56598","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1083\/jcb.146.5.1161","article-title":"CD38\/ADP-ribosyl cyclase: A new role in the regulation of osteoclastic bone resorption","volume":"146","author":"Sun","year":"1999","journal-title":"J. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1096\/fj.02-0205com","article-title":"Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption","volume":"17","author":"Sun","year":"2003","journal-title":"FASEB J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: Therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-18-0773","article-title":"CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma","volume":"79","author":"Marlein","year":"2019","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.4049\/jimmunol.0803897","article-title":"Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells","volume":"182","author":"Kiesel","year":"2009","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1172\/JCI60920","article-title":"Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function","volume":"122","author":"Charles","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/carcin\/bgx045","article-title":"Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells\u2019 phenotype and translation initiation","volume":"38","author":"Dabbah","year":"2017","journal-title":"Carcinogenesis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2019.01.003","article-title":"BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner","volume":"207","author":"Ibraheem","year":"2019","journal-title":"Transl. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epi-thelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2141.1999.01491.x","article-title":"Human osteoclasts derive from CD14-positive monocytes","volume":"106","author":"Massey","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhuang, J., Zhang, J., Lwin, S.T., Edwards, J.R., Edwards, C.M., Mundy, G.R., and Yang, X. (2012). Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048871"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13772","DOI":"10.18632\/oncotarget.3830","article-title":"In-volvement of multiple myeloma cell-derived exosomes in osteoclast differentiation","volume":"6","author":"Raimondi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7150\/thno.27550","article-title":"Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2013.24","article-title":"Hypoxia-inducible factor (HIF)-1\u03b1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction","volume":"27","author":"Storti","year":"2013","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1126\/science.1142612","article-title":"Developmentally Regulated piRNA Clusters Implicate MILI in Transposon Control","volume":"316","author":"Aravin","year":"2007","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.cell.2007.01.043","article-title":"Discrete Small RNA-Generating Loci as Master Regulators of Transposon Activity in Drosophila","volume":"128","author":"Brennecke","year":"2007","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1158\/0008-5472.CAN-09-2670","article-title":"Pathways of Proliferation and Antiapoptosis Driven in Breast Cancer Stem Cells by Stem Cell Protein Piwil2","volume":"70","author":"Lee","year":"2010","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2011.10.004","article-title":"piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells","volume":"315","author":"Cheng","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/leu.2014.135","article-title":"piRNA-823 contributes to tumor-igenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma","volume":"29","author":"Yan","year":"2015","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.18632\/oncotarget.3300","article-title":"Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells","volume":"6","author":"Lub","year":"2015","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cell regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2018.11.002","article-title":"Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway","volume":"442","author":"Menu","year":"2019","journal-title":"Cancer Lett."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/2969\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:13:57Z","timestamp":1760163237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/2969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,13]]},"references-count":66,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13122969"],"URL":"https:\/\/doi.org\/10.3390\/cancers13122969","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,13]]}}}